Led · Series B · Feb 2018

DiaCarta develops XNA (xeno nucleic acid)–based detection and amplification technologies, including QClamp® and OptiSeq™, to enable highly sensitive detection of actionable mutations via qPCR and next‑generation sequencing. The company offers CLIA laboratory testing services, an ISO 13485‑certified facility for IVD product development and a clinical service laboratory in Nanjing, China. Core products and pipeline items mentioned include ColoScape™ (a liquid biopsy and tissue assay for colorectal cancer), gene mutation and fusion panels, and a multiplexing HPV E6/E7 mRNA genotyping test. DiaCarta plans global clinical study programs for non‑invasive early cancer detection, recurrence monitoring indications, and expansion into global markets with FDA and CFDA certification efforts. The company is investing in expanding its CLIA and OptiSeq NGS offerings and commercial team to support a growing product portfolio. Financially, DiaCarta completed a $45.0M Series B financing to support these product, regulatory, IP, and commercial initiatives. DiaCarta develops sensitive mutation-detection and viral mRNA assays for clinical diagnostics. Its QClamp™ mutation-detection assays use xeno-nucleic acid (XNA) clamping technology to suppress amplification of wild-type DNA and selectively amplify mutant DNAs in real-time PCR for targets including EGFR, KRAS, NRAS, BRAF, PIK3CA and JAK-2. The QuantiVirus® HPV E6/E7 mRNA tests detect HPV E6/E7 mRNA in cervical and oral cancer using branched DNA signal amplification without RNA purification or RT-PCR and do not require a clean room environment. DiaCarta’s assays are CFDA- and CE/IVD-cleared. The company intends to use the $8M Series A proceeds to expand its product portfolio and support global commercialization. Led by Aiguo Zhang, Ph.D., as President & CEO, DiaCarta is based in Hayward, California.